

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
"Lasting relief requires transparent, enforceable measures that lower drug prices and hold big drug companies accountable," said one critic.
US President Donald Trump on Monday announced nine more agreements with pharmaceutical manufacturers intended to lower prescription drug prices nationwide, bringing the total to 26, but patient advocates responded skeptically.
The administration previously struck "most favored nation" (MFN) deals with 17 large drug manufacturers. The new ones with midsized companies—Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB—mean that 89% of the branded drug market is subject to an agreement, according to a White House fact sheet.
"It has been nearly a year since Trump announced his first secret MFN deal with Pfizer, and he has almost nothing to show for it," Peter Maybarduk, Access to Medicines director at the watchdog group Public Citizen, said in a Monday statement. "The new deals are a distraction from the administration's failed plan to lower US drug prices to the levels paid in other wealthy countries."
Earlier this month, Public Citizen released an analysis of Trump's policies to cut drug costs, including MFN deals. Maybarduk said at the time that "Trump has three kinds of drug pricing policy: fake, exaggerated, and not-real-yet, probably-won't-happen."
Following Monday's agreements, the campaigner argued that "a more serious approach would build international reference pricing into Medicare drug price negotiation. Instead, Trump is cozying up to Big Pharma and keeping American drug prices high."
"There still is no evidence that any pharma company has followed through on prior commitments to the Trump administration to launch new drugs at MFN price points," he explained. "Uptake of TrumpRx, which may cause consumers to overpay on medicines, has been lackluster."
TrumpRx is a government-operated website that helps patients find discounted prices and coupons for certain medications—and, as the Public Citizen analysis highlighted, the only part of the president's MFN program that is fully underway.
"The Centers for Medicare and Medicaid Services (CMS) has not announced any state participants in a pilot to test MFN-based prices in Medicaid," Maybarduk noted. "And CMS has failed to issue final rules to test MFN-pricing in Medicare, while simultaneously excluding almost all drug companies from these programs."
Public Citizen said it plans to immediately file a Freedom of Information Act request to obtain the texts of these "farce" deals—a pledge that came just days after US Sen. Elizabeth Warren (D-Mass.) highlighted that Health and Human Services Secretary Robert F. Kennedy Jr. has failed to publicize initial 17 agreements, despite agreeing to do so during an April hearing.
Like Public Citizen, the advocacy group Patients for Affordable Drugs was critical of the new deals, with CEO Merith Basey pointing out that "for decades, drug companies have been charging Americans at least four times more for brand-name medicines than people in other high-income nations."
"Patients need systemic reforms that will lower drug prices, rather than short-term, voluntary agreements whose terms remain secret," she asserted. "The deals announced today focus on Medicaid, where steep discounts already exist, and even then, states can choose whether to participate. Lasting relief requires transparent, enforceable measures that lower drug prices and hold big drug companies accountable."
As the industry trade publication Fierce Pharma reported, the large companies behind the initial deals "made a combination of drug pricing commitments and domestic investment pledges to win temporary immunity from the Trump administration's drug import tariffs," and "individual company press releases Monday, like UCB's, suggest that tariff immunity is still very much part of the MFN equation."
Although Trump's tried taking credit for a recent drop in medication costs, with the White House X account claiming Monday that he's "leveled the playing field, and made prescription drugs more affordable than ever for the American people," as Common Dreams reported earlier this month, experts have cited the Biden administration's policy allowing Medicare to directly negotiate some prices.
As Trump has touted his MFN deals, critics of the United States' for-profit healthcare system have in recent months renewed calls for shifting to Medicare for All—which new research shows would save over 114,000 lives and $1 trillion each year—and other healthcare reforms, including breaking up industry giants, capping drug prices, strengthening antitrust enforcement, and expanding the sector's workforce.
"Why should Americans believe this isn't just another Trump handout to fatten Big Pharma's pockets?"
Nearly two weeks after US Sen. Elizabeth Warren wrote to the Trump administration's top health official in her latest attempt to get answers on "secret pricing deals" with Big Pharma, the Massachusetts Democrat said Wednesday that she is still waiting for the White House to make the terms of the agreements public.
On social media, Warren noted that she asked Health and Human Services Secretary Robert F. Kennedy Jr. to publicize the deals for medicines listed on President Donald Trump's direct-to-consumer website, TrumpRx, at a hearing in April.
"Will you make the deals available to us so we can see them, a little transparency?" the senator had asked.
Kennedy replied that he would be "happy to make the deals available except for proprietary information and trade secrets."
But as the agreements have appeared to do little to reduce drug costs, Kennedy responded to Warren's request in writing without providing "copies of the questionable agreements" or answers to her questions about "unproven claims that the website is saving patients money," the senator noted.
Instead, Kennedy's response raised "fresh questions about whether the Trump administration’s savings estimates are reliable."
Months after her initial request, Warren said Wednesday, "still crickets."
"Why should Americans believe this isn't just another Trump handout to fatten Big Pharma's pockets?" she asked.
As Common Dreams reported last week, experts have pointed to the Biden administration's policy allowing Medicare to directly negotiate the prices of some drugs as the major driver of falling prescription prices, which dropped 3.1% over the past year.
But Trump has claimed that the "most favored nation" deals his administration negotiated with 17 pharmaceutical companies were behind the falling prices, despite the fact that just one aspect of his MFN policy—TrumpRx—has been enacted, and the website has only been found to deliver savings on one out of 54 listed medications.
"While TrumpRx has since added a wider selection of generic drugs and added some information about generic alternatives to select pages, not every brand drug on TrumpRx with an existing generic alternative has that alternative readily available on the site, and a recent analysis finds that the TrumpRx deals represent only around 12% of brand drugs made by participating Big Pharma companies," wrote Warren to Kennedy on August 13. "Thus, consumers still risk overpaying for branded drugs despite the availability of cheaper generics."
She added that the administration recently made the "unfounded claim that TrumpRx has already saved more than $700 million for American patients," while saving the average user of prescription medications only about $5.
"Your response to me raises questions about whether even that estimate was made up out of thin air," wrote Warren, noting that Kennedy had admitted TrumpRx “does not store any patient, health, or prescription information."
She emphasized that drug manufacturers who signed the MFN deals with Trump "have benefited from huge tariff exemptions for branded drugs and received vouchers to fast-track approvals for new products. That is on top of billion-dollar handouts President Trump and Republicans in Congress gave to the pharmaceutical industry last year in their tax law."
"This is a huge win for giant drug companies that will reap billions in additional revenues from higher prices abroad, while doing absolutely nothing to lower drug prices for Americans in need," wrote the senator. "Americans are paying more on everything from school supplies to furniture thanks to Trump’s across-the-board tariffs, and instead of negotiating deals to help workers and American families, he’s using that leverage to go to bat for Big Pharma."
"Americans deserve to know whether the deals the administration is cutting with Big Pharma will lower their prescription drug costs—or just further enrich big drug companies," said Warren. "Despite my request that you make the administration’s MFN deals with giant drug companies public, and your commitment to do so, you have yet to follow through."
"You can't just redefine how you calculate percentages," said one mathematician in response to Kennedy's claims.
US Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday tried to defend President Donald Trump's mathematically absurd claims about prescription drug prices by saying the president has his own unique method of calculating percentages.
During a Senate Finance Committee hearing, Sen. Elizabeth Warren (D-Mass.) grilled Kennedy about the president's repeated false claims that he has slashed the prices of prescription drugs by as much as 600%, which would mean that pharmaceutical companies are paying consumers to take their medications.
"President Trump has his own way of calculating," Kennedy replied. "There's two ways of calculating percentages. If you have a $600 drug, and you reduce it to $10, that's a 600% reduction."
RFK Jr: "President Trump has a different way of calculating percentages. If you have a $600 drug and you reduce it to $10, that's a 600% reduction." pic.twitter.com/MjDNADqc8p
— Aaron Rupar (@atrupar) April 22, 2026
In fact, such a drop in price would represent a 98.3% reduction, less than one-sixth the size of the president's claims. A 600% reduction in the price of a $600 drug would mean that drug manufacturer paid consumers $3,000 every time they picked up their prescription.
Kit Yates, a mathematician at the University of Bath, marveled at Kennedy's attempts to create an alternate version of arithmetic.
"We've known for a while that the USA's current regime have been out for science, but I never thought they would try to mess with math!" Yates wrote in a social media post. "You can't just redefine how you calculate percentages."
In addition to exposing Kennedy's apparent ignorance of elementary mathematics, Warren shined a light on how the TrumpRx website misleads consumers into thinking they're being offered bargains on prescription drugs that are available elsewhere in generic varieties.
In once instance, Warren noted that TrumpRx is selling a brand-name heartburn medication for $200, whereas a generic version of the same drug is available at Costco for $16. Warren also highlighted a heart arrhythmia drug for sale on TrumpRx for $336, even though a generic version of the drug is available at Costco for $12.
Warren added that, in exchange for making select brand-name drugs available on the TrumpRx website, pharmaceutical companies have gotten exemptions from the president's 100% tariffs on imported patented medicines.
"Think about that: Big Pharma makes billions of dollars in tariff relief by listing their drugs on TrumpRx, and then they don't even lower the costs on many of these drugs," she said. "That is a great deal for Big Pharma."
Warren's analysis of TrumpRx's pricing scheme echoes a March report from the Center for American Progress (CAP), which found that the president's prescription drug website offered genuinely lower prices on “exactly one” of the 54 medications listed.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
Reuters reported in December that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
Later in the Senate Finance Committee hearing, Sen. Bernie Sanders (I-Vt.) ridiculed Kennedy for claiming that, under Trump's leadership, "the American people are now paying the lowest costs in the world rather than the highest for prescription drugs."
"That is an absurd statement," Sanders said. "Nobody in the world believes that."
"As they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them, and patients are paying the price."
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
"For the 22 million Americans whose premiums have doubled, and the millions more who stand to lose coverage, a $56 discount on a fertility drug is not 'immediate relief.'"
US President Donald Trump launched TrumpRx last month with a bold promise to the American public: "dramatically lower prices on dozens of common, high-cost, brand-name prescription drugs."
But an analysis released Tuesday by the Center for American Progress (CAP) found that of the 54 medications listed on TrumpRx.gov as of March 16, "exactly one" drug—the fertility medication Cetrotide—is available at a "genuinely new lower price" not available elsewhere.
The CAP analysis emphasized that TrumpRx—touted by the administration as a path to "immediate relief" for consumers in the country with the highest drug prices in the world—is extremely limited by design, listing just 0.2% of all federally approved medications in the US.
Additionally, the terms that site users must accept before gaining access to coupons for discounted prices state that beneficiaries cannot be "enrolled in insurance from any government, state, or federally funded medical or prescription benefit programs."
Patients also must have a prescription to use TrumpRx for discounts. "According to a KFF analysis," CAP noted, "nearly half (46.6%) of uninsured adults ages 18 to 64 reported not seeing a doctor or other health professional in 2023."
"Applied to the estimated 27.9 million adults without insurance in 2026, this means that approximately 13 million Americans will never reach the most basic prerequisite for using TrumpRx: a visit with a clinician who can write a prescription," CAP added.
The think tank's analysis found that 17 of the drugs on TrumpRx—or over 30% of them—have generic equivalents that are available at a lower cost elsewhere, something that the Trump-branded platform doesn't tell users.
"Among the remaining 37 drugs without lower-cost generics, GoodRx offers comparable or lower prices for 20," CAP found. "That leaves 17 drugs where TrumpRx appears to offer a better deal. But in 16 of those cases, the same or lower prices were already available through manufacturer coupons and patient assistance programs. After accounting for all existing discount channels, just one drug—Cetrotide, a fertility medication—offers a price that was not previously available to cash-paying patients."
Neda Ashtari, associate director of health policy at CAP and author of the new analysis, said in a statement that the Trump administration is "undermining the most powerful tool for lowering patients’ costs at the pharmacy counter—health insurance coverage—and replacing it with a government-branded coupon book."
“For the 22 million Americans whose premiums have doubled, and the millions more who stand to lose coverage," due to Trump and the GOP's refusal to extend enhanced Affordable Care Act subsidies, "a $56 discount on a fertility drug is not 'immediate relief,'" Ashtari added.
CAP's analysis was released a day before The New York Times and the German news organizations Süddeutsche Zeitung, NDR, and WDR debunked Trump's claim last month to have delivered the lowest drug prices "in the entire world"—which would be news to the 1 in 3 US adults who say they've rationed medications, skipped meals, or made other painful tradeoffs over the past year to afford healthcare expenses.
"The drugs listed on TrumpRx can cost American patients up to hundreds or thousands of dollars, while a patient walking into a German pharmacy pays next to nothing," the Times observed on Wednesday. "The German health system foots the bill, and records show that, more often than not, it pays less than what the Trump administration negotiated for Americans."